Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.

The aberrant release of inflammatory mediators often referred to as a cytokine storm or cytokine release syndrome (CRS), is a common and sometimes fatal complication in acute infectious diseases including Ebola, dengue, COVID-19 and influenza. Fatal CRS occurrences have also plagued the development of highly promising cancer therapies based on T cell engagers and chimeric antigen receptor (CAR) T cells. CRS is intimately linked with dysregulated and excessive cytokine release including interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), interleukin (IL) 1, IL-6 and IL-10 resulting in a systemic inflammatory response leading to multiple organ failure. Here we show that mice intravenously administered the agonistic hamster anti-mouse CD3e monoclonal antibody 145-2C11 develop clinical and laboratory manifestations seen in patients afflicted with CRS, including body weight loss, hepatosplenomegaly, thrombocytopenia, increased vascular permeability, lung inflammation and hypercytokinemia. Blood cytokine levels and gene expression analysis from lung, liver and spleen demonstrated a hierarchy of inflammatory cytokine production and infiltrating immune cells with differentiating organ-dependent kinetics. IL-2, IFN-γ, TNF-α and IL-6 up-regulation preceded clinical signs of CRS. The co-treatment of mice with a neutralizing anti-cytokine antibody cocktail transiently improved early clinical and laboratory features of CRS. We discuss the predictive use of this model in the context of new anti-cytokine strategies to treat human CRS. This article is protected by copyright. All rights reserved.